Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Avastin for Central and Branch Retinal Vein Occlusion
2005-003288-21Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Aug 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), sponsored by Medical University of Vienna. Primary endpoint: Visual acuity outcomes (ETDRS). Started Aug 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
central retinal vein occlusion (CRVO)branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on 2005-003288-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003288-21.